World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
56
Citations
15078
World Ranking
3667
National Ranking
1439

Overview

Hongmei Mo is affiliated with Gilead Sciences in the United States and has a research focus centered on infectious diseases, particularly viral infections affecting the liver and respiratory system. Their body of work spans several crucial areas within medicine, with a notable emphasis on hepatitis viruses and SARS-CoV-2.

The scientist's main fields of study include:

  • Medicine

Within their medical research, key subfields are:

  • Epidemiology
  • Hepatology
  • Infectious Diseases
  • Molecular Biology
  • Surgery

The following topics represent primary focuses of their research:

  • Hepatitis B Virus Studies
  • Hepatitis C Virus Research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis Viruses Studies and Epidemiology
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Viral Infections and Immunology Research

Hongmei Mo has contributed to multiple peer-reviewed scientific journals, with frequent publications in:

  • Journal of Hepatology
  • JHEP Reports
  • Journal of Viral Hepatitis
  • Journal of Virology
  • bioRxiv (Cold Spring Harbor Laboratory)

Several recent papers illustrate the scope and thematic interests of their research:

  • "Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants" (2022, Antimicrobial Agents and Chemotherapy)
  • "Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir" (2021, Antiviral Research)
  • "Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection" (2021, JHEP Reports)
  • "Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B" (2022, JHEP Reports)
  • "Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines" (2021, Journal of Virology)

Collaboration has been a notable aspect of Hongmei Mo's work, frequently partnering with other researchers such as Ross Martin, Savrina Manhas, Becket Feierbach, Lindsey May, and Yang Liu. These collaborations reflect a multidisciplinary approach connecting epidemiology, molecular biology, and clinical research perspectives.

Best Publications

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Genotypic and phenotypic characterization of HIV-1 patients with primary infection

    Tuofu Zhu;Hongmei Mo;Ning Wang;Daniel S. Nam

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

    Eric Lawitz;Fred F Poordad;Phillip S Pang;Robert H Hyland

  • Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

    Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto

  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

    Eric Lawitz;Jay P Lalezari;Tarek Hassanein;Kris V Kowdley

  • Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

    Sergio M Borgia;Charlotte Hedskog;Bandita Parhy;Robert H Hyland

  • Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Erik Lontok;Patrick Harrington;Anita Howe;Tara Kieffer

  • Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

    M. Markowitz;Hongmei Mo;D. J. Kempf;D. W. Norbeck

  • Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

    Christoph Sarrazin;Hadas Dvory-Sobol;Evguenia S. Svarovskaia;Brian P. Doehle

  • Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

    Liangjun Lu;Tami J. Pilot-Matias;Kent D. Stewart;John T. Randolph

  • Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

    Evguenia S. Svarovskaia;Hadas Dvory-Sobol;Neil Parkin;Christy Hebner

  • NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

    Stefan Zeuzem;Masashi Mizokami;Stephen Pianko;Alessandra Mangia

  • A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

    Eric J. Lawitz;Daniel Gruener;John M. Hill;Thomas Marbury

  • Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

    Unknown

  • Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

    Teresa I. Ng;Hongmei Mo;Tami Pilot-Matias;Yupeng He

  • Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

    Megan H. Powdrill;Egor P. Tchesnokov;Robert A. Kozak;Rodney S. Russell

  • Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

    Hongmei Mo;Liangjun Lu;Tami Pilot-Matias;Ron Pithawalla

  • Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses

    Tania M. Welzel;Neeru Bhardwaj;Charlotte Hedskog;Krishna Chodavarapu

  • The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

    Stefan Zeuzem;Peter Buggisch;Kosh Agarwal;Patrick Marcellin

  • Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

    Christoph Sarrazin;Vasily Isakov;Evguenia S. Svarovskaia;Charlotte Hedskog

  • Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

    Christophe Hezode;Nancy Reau;Evguenia S. Svarovskaia;Brian P. Doehle

Frequent Co-Authors

Michael D. Miller
Michael D. Miller United States Military Academy
John G. McHutchison
John G. McHutchison Duke University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Tami Pilot-Matias
Tami Pilot-Matias AbbVie (United States)
Ira M. Jacobson
Ira M. Jacobson New York University
Adrian S. Ray
Adrian S. Ray Yale University
Jacques Fellay
Jacques Fellay École Polytechnique Fédérale de Lausanne
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens the door to various specialized career paths beyond traditional laboratory roles. For those interested in healthcare administration and data management, pursuing accredited programs can be a strategic move. One promising avenue is to explore the certified professional coder (cpc) track, which focuses on medical coding and billing, essential for accurate healthcare documentation and reimbursement processes.

Many professionals combine microbiology knowledge with healthcare information skills, benefitting from higher salaries in leadership roles. The role of a health information manager is particularly noteworthy, with competitive pay and a critical place in health data oversight. To further this career, it’s beneficial to look into the best online cahiim accredited health information management degree programs, which provide recognized credentials that meet industry standards.

For quicker entry into the field, enrolling in an accredited fast medical billing and coding certificate online program can jumpstart your career with practical skills and certification. These programs cater to busy students and professionals looking to transition or upskill efficiently.

Ultimately, combining microbiology expertise with credentialed programs in health information and coding allows graduates to pursue diverse and lucrative career pathways across healthcare and biomedical sectors.

Best Scientists Citing Hongmei Mo

Trending Scientists

Recently Published Articles